Tc 99m P 483H
Alternative Names: Infetect; P483H peptide; Tc-99m-P483H; Technetium Tc 99m P483HLatest Information Update: 18 Sep 2006
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals; Nihon Medi-Physics
- Class Organotechnetium compounds; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Infections
Most Recent Events
- 18 Sep 2006 Discontinued - Phase-II for Infections diagnosis in European Union (unspecified route)
- 18 Sep 2006 Discontinued - Phase-II for Infections diagnosis in USA (unspecified route)
- 18 Sep 2006 Discontinued - Preclinical for Infections diagnosis in Japan (unspecified route)